Despite Ireland’s stellar biopharmaceutical success, the new president of the Irish Pharmaceutical Healthcare Association ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Safety profile similar to other trials, with six in 10 sustaining medication overuse headache remission over six months ...

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.

In addition to Dr. Bachleda, members of the Eyconis Board of Directors include Dr. Cunningham, who serves as Executive Chair, Jan Mikkelsen, President & CEO of Ascendis Pharma A/S, Daniel Estes, Ph.D.

ALS, MS, post-traumatic brain injury? This biotech company has a target choice to make for an upcoming clinical trial — and ...

Amgen Inc. closed $13.93 short of its 52-week high ($346.85), which the company reached on July 25th.

The Congressional Black Caucus Foundation's Annual Legislative Conference panel on the Road to Health Equity discussed the ...

On June 28, 2024, the United States Patent and Trademark Office (“USPTO”) requested the public’s views on the current state ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...